GSK plc Sponsored ADR (GSK)
GSK: Maintaining Strong Buy For LAI HIV Sales Growth And Further Oncology Expansion
GSK plc demonstrates strong oncology pipeline momentum, highlighted by Mo-Rez's phase 1 success in platinum-resistant ovarian and endometrial cancers. Mo-Rez's impressive response rates support five global pivotal phase 3 trials planned for 2026, underscoring GSK's late-stage oncology expansion. GSK's ViiV Healthcare reports Cabenuva's superior viral suppression in HIV, and the company advances key acquisitions and registrational data in multiple myeloma and lung cancer.
GSK to cut up to 1,217 jobs in Belgium, L'Echo says
GSK to cut up to 1,217 jobs in Belgium, L'Echo says
GSK third quarter likely to be in line as RBC sees vaccine headwinds offset by HIV strength
GSK PLC (LSE:GSK, NYSE:GSK) is expected to deliver a broadly in-line third quarter as weaker vaccine sales are offset by strength in HIV treatments and respiratory drug Nucala, according to RBC Capital Markets. The broker reiterated its Sector Perform rating and 1,975p price target ahead of GSK's results on 28 October, compared with a share price of 1,771p when the note was published.
Is the Options Market Predicting a Spike in GSK Plc Stock?
Investors need to pay close attention to GSK stock based on the movements in the options market lately.
GSK: The Gas Pedal Is Finally Down
GSK is accelerating its strategic transformation under new CEO Luke Miels, emphasizing M&A, pipeline expansion, and proactive HIV franchise management. At approximately 7x NTM EV/EBITDA, GSK offers an attractive risk/reward for investors willing to accept execution risk, meriting a Buy rating. The company is targeting over 20 Phase III starts in 2026, reinvesting GBP 1.9bn annual cost savings into R&D and M&A to offset the upcoming HIV patent cliff.
GSK retains ‘buy' rating at Jefferies as B7H3 cancer programme seen as underappreciated
Investment bank Jefferies has kept its ‘buy' rating and 2,500p target on GSK PLC (LSE:GSK, NYSE:GSK), the FTSE 100 drugmaker, after a fireside chat with its chief scientific officer reinforced its view that B7H3 is one of GSK's most underappreciated opportunities. The target implies 35% upside from the prior close of 1,851p, while GSK had a market capitalisation of £74.9 billion.
GSK plc (GSK) Presents at Bernstein Insights: Healthcare Leaders and Disruptors - 3rd Annual Healthcare Forum Transcript
GSK plc (GSK) Presents at Bernstein Insights: Healthcare Leaders and Disruptors - 3rd Annual Healthcare Forum Transcript
GSK Bets on Long-Acting Biologics and AI to Reshape Respiratory Care
GSK NYSE: GSK is advancing a respiratory and immunology pipeline centered on longer-acting biologics, more targeted patient selection and combination approaches, according to Kaivan Khavandi, the company's senior vice president and global head of Translational and Development Sciences.
GSK plc (GSK) Presents at Bank of America Global Healthcare Conference 2026 Transcript
GSK plc (GSK) Presents at Bank of America Global Healthcare Conference 2026 Transcript
GSK Targets £40B Sales as Oncology Push and £1.9B Savings Plan Take Shape
GSK NYSE: GSK Chief Financial Officer Julie Brown outlined the company's growth strategy, launch priorities and cost-savings plans during a discussion with Bank of America analyst Sachin Jain following the company's recent capital markets day.
GSK Targets Oncology Growth With Lung, Prostate and Gynecologic Cancer Pipeline
GSK NYSE: GSK is pursuing a focused oncology expansion built around hematologic malignancies, gynecologic cancers, lung cancer, gastrointestinal cancers and prostate cancer, with a combination of internal research and business development, according to Hesham Abdullah, the company's senior vice president and global head of oncology research and development.
GSK plc (GSK) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
GSK plc (GSK) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
